Torsades de pointes associated with voriconazole use

Area of Science:

• Cardiology
• Pharmacology
• Oncology

Background:

• Voriconazole is a widely used antifungal medication.
• Acute cardiomyopathy and invasive aspergillosis are serious conditions.
• Chemotherapy, particularly anthracycline-based regimens, can impact cardiac function.

Observation:

• Two patients receiving voriconazole developed a prolonged QTc interval.
• One patient experienced torsades de pointes (a type of arrhythmia) during voriconazole therapy.
• The second patient showed a significantly prolonged QTc interval while on voriconazole.

Findings:

• Voriconazole treatment was associated with QTc interval prolongation in these cases.
• Re-challenge with voriconazole in one patient did not result in recurrent QTc prolongation.
• The potential for synergistic cardiotoxicity with other treatments should be considered.

Implications:

• Close electrocardiogram (ECG) monitoring for QTc prolongation is recommended for patients on voriconazole.
• Particular vigilance is needed in patients with electrolyte disturbances, concurrent QT-prolonging drugs, heart failure, or recent anthracycline chemotherapy.
• Risk stratification and careful consideration of potential drug interactions are essential for safe voriconazole use.